For a 61-year-old man with type 1 diabetes, weight 62.2 kg, normal renal function, currently taking insulin glargine (Lantus) 6 U at 1800 h, with an insulin‑to‑carbohydrate ratio of 1 U per 14 g carbohydrate and an insulin sensitivity factor of 100 mg/dL per unit, and blood glucose values consistently 285–308 mg/dL, what should the insulin sensitivity factor, insulin‑to‑carbohydrate ratio, and basal insulin dose be adjusted to?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Insulin Dose Adjustments for Uncontrolled Type 1 Diabetes

This patient's insulin regimen is grossly inadequate and requires immediate, substantial upward titration of all three components: increase Lantus to at least 12-15 units, tighten the ICR to 1:10-12g, and strengthen the ISF to 1:50-60 mg/dL.

Current Problem Analysis

Your patient's blood glucose values (285-308 mg/dL throughout the day, even 237 at best) indicate severe insulin deficiency across all components:

  • Basal insulin failure: Morning glucose of 285 mg/dL and 2 AM glucose of 308 mg/dL demonstrate inadequate overnight basal coverage
  • Bolus insulin failure: Post-meal values remaining at 289-308 mg/dL despite carbohydrate intake show insufficient meal coverage
  • Correction insulin failure: ISF of 1:100 is far too weak to bring down these elevated values

Basal Insulin (Lantus) Adjustment

Increase Lantus from 6 units to 12-15 units immediately.

The current 6 units represents only ~10% of what this patient likely needs. For a 62.2 kg patient with type 1 diabetes:

  • Total daily insulin requirement: Approximately 0.5-0.7 units/kg = 31-44 units total daily dose 11
  • Basal insulin should comprise: 24-30% of total daily dose 23, which equals approximately 8-13 units minimum
  • FDA guidance: Start at 0.1-0.2 units/kg for basal insulin = 6-12 units, then titrate upward 11
  • ADA 2025 guideline: Increase by 2 units every 3 days until fasting glucose reaches goal 4

Given the severely elevated fasting glucose (285 mg/dL at 0700 and 308 mg/dL at 0200), I recommend an aggressive initial increase to 12-15 units, then titrate up by 2 units every 3 days targeting a fasting glucose of 80-130 mg/dL 4.

Insulin-to-Carbohydrate Ratio (ICR) Adjustment

Tighten the ICR from 1:14g to 1:10-12g.

The current ratio is too weak, evidenced by:

  • After eating 54g CHO at breakfast, glucose remained 289 mg/dL (essentially unchanged from 285 mg/dL)
  • After 56g CHO at lunch, glucose stayed at 308 mg/dL
  • After 30g CHO at dinner, glucose remained 237 mg/dL

With an estimated total daily dose of 35-40 units, the ICR should be calculated as:

  • 500 Rule: 500 ÷ TDD = 500 ÷ 35-40 = 1:12-14g

However, given the persistent hyperglycemia despite current dosing, start with 1:10-12g and adjust based on 2-hour post-meal glucose readings.

Insulin Sensitivity Factor (ISF) Adjustment

Strengthen the ISF from 1:100 to 1:50-60 mg/dL.

The current ISF is dangerously weak for correction doses:

  • 1800 Rule: 1800 ÷ TDD = 1800 ÷ 35-40 = 1:45-51 mg/dL per unit

Start with ISF of 1:50-60 mg/dL to provide adequate correction for these persistent 250-300+ mg/dL readings. This means each unit of rapid-acting insulin should lower glucose by 50-60 mg/dL.

Implementation Algorithm

  1. Tonight: Increase Lantus to 12 units at 1800h
  2. Tomorrow: Begin using ICR 1:10g and ISF 1:50 mg/dL for all meals
  3. Every 3 days: Increase Lantus by 2 units if fasting glucose >130 mg/dL 4
  4. After 1 week: Reassess ICR based on 2-hour post-meal values (target <180 mg/dL)
  5. After 1 week: Reassess ISF based on correction dose effectiveness

Critical Safety Considerations

  • Hypoglycemia risk: With GFR 73 mL/min (mild CKD), insulin clearance is slightly reduced 1. Monitor closely for hypoglycemia, especially overnight
  • Dose reduction for hypoglycemia: If blood glucose <70 mg/dL occurs, reduce the corresponding insulin component by 10-20% 4
  • Glucagon prescription: Ensure patient has emergency glucagon available 41
  • Frequent monitoring: Check blood glucose before each meal, 2 hours post-meal, bedtime, and occasionally at 2-3 AM during titration

Common Pitfalls to Avoid

  • Therapeutic inertia: Don't make timid 1-2 unit adjustments when the patient needs 6-10 unit increases
  • Ignoring basal-bolus balance: All three components (basal, ICR, ISF) are inadequate and must be addressed simultaneously
  • Waiting too long between adjustments: With values this high, adjust every 3 days rather than weekly 4
  • Mixing or diluting Lantus: Never mix Lantus with other insulins or dilute it 11

The patient's renal function (GFR 73) is adequate for standard insulin dosing, though slightly reduced clearance means closer monitoring is warranted 1.

References

Related Questions

For a 19‑year‑old patient with type 1 diabetes weighing 86.2 kg who is currently taking insulin glargine (Lantus) 12 U at 08:00 and 35 U at 20:00 and uses insulin‑to‑carbohydrate ratios of 1 U per 5 g carbs for breakfast and lunch and 1 U per 6 g carbs for dinner, what should the basal Lantus dose and insulin‑to‑carbohydrate ratio be adjusted to?
For a patient on insulin glargine (Lantus) 18 units with an insulin‑sensitivity factor of 25 mg/dL per unit and an insulin‑to‑carbohydrate ratio of 10 g per unit, who has blood glucose readings of 234 mg/dL at 5 PM after eating 66 g of carbohydrate, 240 mg/dL at 9 PM, and 201 mg/dL at 2 AM, what should the insulin‑sensitivity factor, insulin‑to‑carbohydrate ratio, and basal Lantus dose be adjusted to?
In a 58-year-old patient with diabetes mellitus using insulin glargine (basal) and insulin aspart (prandial), what is the appropriate timing for each insulin dose?
For a 61-year-old female with type 1 diabetes, weight 79 kg, impaired renal function, overnight blood glucose 115‑124‑113 mg/dL, currently on insulin glargine (Lantus) 13 U daily, insulin‑to‑carbohydrate ratio 1 U per 10 g carbohydrate, and a medium correction factor, who is eating little and will undergo continuous renal replacement therapy (CRRT) today, how should the basal insulin dose, insulin‑to‑carbohydrate ratio, and insulin sensitivity factor be adjusted?
For a type 1 diabetic patient on insulin glargine (Lantus) currently reduced to 55 U, with blood glucose readings of 180 mg/dL at 8 am, 184 mg/dL at 12 pm, 113 mg/dL at 5 pm, 88 mg/dL at 10 pm, and 112 mg/dL at 2 am after eating 125 g, 80 g, and 132 g of carbohydrates at breakfast, lunch, and dinner respectively, what should the insulin‑to‑carbohydrate ratios and basal insulin glargine dose be?
Are the patient’s mixed symptoms (intermittent pruritus, rash, nasal congestion, wheezing, and abdominal cramping) attributable to his longstanding high eosinophilia that began in adolescence?
Can a 13-year-old take Mobic (meloxicam)?
What are the optimal pharmacologic treatments for persistent eosinophilia?
Are bilateral pars interarticularis defects clinically significant, and how should they be managed?
What are the current treatment guidelines for a patient with seronegative rheumatoid arthritis following chickenpox, presenting with polyarthralgia and burning sensations in the soles and palms for over a year, who is already on triple disease‑modifying antirheumatic drugs (methotrexate, sulfasalazine, hydroxychloroquine)?
Can deficiencies of vitamin B12 or vitamin D cause hair loss in men?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.